$2.92 Million is the total value of Camber Capital Management LP's 39 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 56.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNY | Sell | SANOFIsponsored adr | $339,010 | -99.9% | 7,000,000 | -6.7% | 11.63% | +33.2% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $239,513 | -99.9% | 1,700,000 | -24.4% | 8.22% | +35.2% |
| VTRS | Sell | VIATRIS INC | $222,600 | -99.9% | 20,000,000 | -33.3% | 7.64% | -2.5% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $161,975 | -99.9% | 1,250,000 | -16.7% | 5.56% | +9.4% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $159,375 | -99.9% | 1,250,000 | -10.7% | 5.47% | +22.0% |
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $63,840 | -99.9% | 7,000,000 | -6.7% | 2.19% | +18.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $63,434 | -100.0% | 1,400,000 | -30.0% | 2.18% | -49.1% |
| PTON | Sell | PELOTON INTERACTIVE INC | $15,880 | -99.9% | 2,000,000 | -33.3% | 0.54% | -14.4% |
| INGN | Sell | INOGEN INC | $6,012 | -100.0% | 305,000 | -63.0% | 0.21% | -66.4% |
| CANO | Sell | CANO HEALTH INC | $5,480 | -100.0% | 4,000,000 | -20.0% | 0.19% | -85.8% |
| OSH | Exit | OAK STR HEALTH INC | $0 | – | -506,000 | -100.0% | -0.38% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -500,000 | -100.0% | -0.38% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -2,865,000 | -100.0% | -0.54% | – |
| SNY | Exit | SANOFIcall | $0 | – | -1,000,000 | -100.0% | -1.16% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -500,000 | -100.0% | -1.24% | – |
| Exit | QUIDELORTHO CORP | $0 | – | -600,000 | -100.0% | -1.31% | – | |
| INCY | Exit | INCYTE CORP | $0 | – | -750,000 | -100.0% | -1.53% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -200,000 | -100.0% | -1.64% | – |
| CHNG | Exit | CHANGE HEALTHCARE INC | $0 | – | -2,325,000 | -100.0% | -1.96% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -800,000 | -100.0% | -2.08% | – |
| CRL | Exit | CHARLES RIV LABS INTL INC | $0 | – | -500,000 | -100.0% | -3.01% | – |
| PFE | Exit | PFIZER INCcall | $0 | – | -2,500,000 | -100.0% | -3.35% | – |
| MRK | Exit | MERCK & CO INCcall | $0 | – | -1,500,000 | -100.0% | -3.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.